Novel PET radiochemistries: Improving understanding and detection of disease

DATE: June 15, 2016
TIME:  08:00AM PDT, 11:00AM EDT, 3:00PM GMT

Positron Emission Tomography (PET) is a 3-dimensional, quantitative imaging technology that has robust clinical translation from mouse models to man. PET is often the favored imaging modality of choice due to its high sensitivity and resolution. Today, PET is seeing a rapid growth in the number of new imaging agents under development, and an increased utilization of PET imaging to interrogate disease progression in small animal preclinical models. Once considered a specialized imaging modality, PET is transitioning to the mainstream of the preclinical molecular imaging field and PerkinElmer’s G-Platform is breaking down some of the barriers to PET adoption. PET is now positioned to be the molecular imaging modality of choice for a variety of emerging applications in drug discovery and basic science research.

In this webinar Drs. Timothy DeGrado from the Mayo Clinic and Roger Schibli from ETH Zurich will discuss novel radiochemistry approaches their groups are employing to gain further understanding of disease development and progression. Dr. DeGrado’s publication in EJNMMI Research in 2015 highlighted a new cell labeling technique that allows longitudinal imaging of cell trafficking over the course of weeks in a quantitative, non-invasive manner. Dr. Schibli’s radiochemistry efforts have led to the development of several new radioisotopes for in vivo imaging applications and therapeutic intervention. Imaging data acquired on the PerkinElmer’s G4 PET/X-ray and G8 PET/CT systems is enabling the development of these novel PET imaging agents with potential clinical applications. Join us for our thought provoking discussion of the current and future states of preclinical PET imaging. Drs. DeGrado and Schibli will also answer your questions at the conclusion of the webinar.